Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-03-20 DOI:10.3233/CBM-230301

Nozomu Kimura, Yoko Tsukita, Risa Ebina-Shibuya, Eisaku Miyauchi, Mitsuhiro Yamada, Daisuke Narita, Ryota Saito, Chihiro Inoue, Naoya Fujino, Tomohiro Ichikawa, Tsutomu Tamada, Hisatoshi Sugiura

{"title":"Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC.","authors":"Nozomu Kimura, Yoko Tsukita, Risa Ebina-Shibuya, Eisaku Miyauchi, Mitsuhiro Yamada, Daisuke Narita, Ryota Saito, Chihiro Inoue, Naoya Fujino, Tomohiro Ichikawa, Tsutomu Tamada, Hisatoshi Sugiura","doi":"10.3233/CBM-230301","DOIUrl":null,"url":null,"abstract":"Background: Biomarkers predicting clinical outcomes of treating non-small cell lung cancer (NSCLC) with combination of immune checkpoint inhibitors (ICIs) and chemotherapy would be valuable.Objective: This study aims to seek predictors of combination of ICI/chemotherapy response in NSCLC patients using peripheral blood samples.Methods: Patients diagnosed with advanced NSCLC between July 2019 and May 2021 receiving combination of ICI/chemotherapy were included and assessed for partial responses (PR), stable disease (SD) or progressive disease (PD). We measured circulating immune cells, plasma cytokines and chemokines.Results: Nineteen patients were enrolled. The proportions of circulating natural killer (NK) cells within CD45 + cells, programmed death 1 (PD-1) + Tim-3 + T cells within CD4 + cells, and the amount of chemokine C-X-C ligand (CXCL10) in the plasma were significantly elevated in PR relative to SD/PD patients (median 8.1%-vs-2.1%, P= 0.0032; median 1.2%-vs-0.3%, P= 0.0050; and median 122.6 pg/ml-vs-76.0 pg/ml, P= 0.0125, respectively). Patients with 2 or 3 elevated factors had longer progression-free survival than patients with 0 or only one (not reached-vs-5.6 months, P= 0.0002).Conclusions: We conclude that NK cells, CD4 + PD-1 + Tim-3 + T cells, and CXCL10 levels in pre-treatment peripheral blood may predict the efficacy of combination of ICI/chemotherapy in NSCLC.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-230301","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Biomarkers predicting clinical outcomes of treating non-small cell lung cancer (NSCLC) with combination of immune checkpoint inhibitors (ICIs) and chemotherapy would be valuable.

Objective: This study aims to seek predictors of combination of ICI/chemotherapy response in NSCLC patients using peripheral blood samples.

Methods: Patients diagnosed with advanced NSCLC between July 2019 and May 2021 receiving combination of ICI/chemotherapy were included and assessed for partial responses (PR), stable disease (SD) or progressive disease (PD). We measured circulating immune cells, plasma cytokines and chemokines.

Results: Nineteen patients were enrolled. The proportions of circulating natural killer (NK) cells within CD45 + cells, programmed death 1 (PD-1) + Tim-3 + T cells within CD4 + cells, and the amount of chemokine C-X-C ligand (CXCL10) in the plasma were significantly elevated in PR relative to SD/PD patients (median 8.1%-vs-2.1%, P= 0.0032; median 1.2%-vs-0.3%, P= 0.0050; and median 122.6 pg/ml-vs-76.0 pg/ml, P= 0.0125, respectively). Patients with 2 or 3 elevated factors had longer progression-free survival than patients with 0 or only one (not reached-vs-5.6 months, P= 0.0002).

Conclusions: We conclude that NK cells, CD4 + PD-1 + Tim-3 + T cells, and CXCL10 levels in pre-treatment peripheral blood may predict the efficacy of combination of ICI/chemotherapy in NSCLC.

查看原文本刊更多论文

与 NSCLC 免疫检查点阻断剂联合化疗相关的外周血生物标志物。

背景：预测免疫检查点抑制剂（ICIs）和化疗联合治疗非小细胞肺癌（NSCLC）临床疗效的生物标志物很有价值：预测免疫检查点抑制剂（ICIs）和化疗联合治疗非小细胞肺癌（NSCLC）临床结果的生物标志物将非常有价值：本研究旨在利用外周血样本寻找非小细胞肺癌（NSCLC）患者对 ICI/化疗联合疗法反应的预测指标：纳入2019年7月至2021年5月期间诊断为晚期NSCLC并接受ICI/化疗联合治疗的患者，并评估部分应答（PR）、疾病稳定（SD）或疾病进展（PD）。我们测量了循环免疫细胞、血浆细胞因子和趋化因子：结果：共招募了 19 名患者。与 SD/PD 患者相比，PR 患者的循环自然杀伤（NK）细胞在 CD45 + 细胞中所占的比例、程序性死亡 1（PD-1）+ Tim-3 + T 细胞在 CD4 + 细胞中所占的比例以及血浆中趋化因子 C-X-C 配体（CXCL10）的含量均显著升高（中位数为 8.1%-vs-2.1%，P= 0.0032；中位数1.2%-vs-0.3%，P= 0.0050；中位数122.6 pg/ml-vs-76.0 pg/ml，P= 0.0125）。有2个或3个升高因子的患者的无进展生存期长于0个或仅有1个因子的患者（未达到-vs-5.6个月，P= 0.0002）：我们得出结论：治疗前外周血中的NK细胞、CD4 + PD-1 + Tim-3 + T细胞和CXCL10水平可预测ICI/化疗联合治疗NSCLC的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464